Skip to content

Advertisement

  • Case report
  • Open Access

Challenging diagnosis of congenital malaria in non-endemic areas

Contributed equally
Malaria Journal201817:470

https://doi.org/10.1186/s12936-018-2614-9

  • Received: 24 July 2018
  • Accepted: 5 December 2018
  • Published:

Abstract

Background

Congenital malaria is usually defined as the detection of asexual forms of Plasmodium spp. in a blood sample of a neonate during perinatal age if there is no possibility of postpartum infection by a mosquito bite. The incidence of congenital malaria is highly variable and seems related to several factors, such as different diagnostic methods for Plasmodium spp. detection, and area in which the epidemiologic analyses are performed. In non-endemic countries, cases of congenital malaria are rare. Hereby, a case of a congenital malaria in an HIV exposed child is reported.

Case presentation

A 2-month-old male child was admitted to Bambino Gesù Children’s Hospital due to anaemia and exposure to HIV. He was born prematurely in Italy by cesarean section at 34 weeks’ gestation after a bicorial, biamniotic pregnancy by a migrant woman from Nigeria. He was the first of non-identical twins. Combined with anaemia, spleen and liver enlargement was noted, malaria was hypothesized. Malaria laboratory panel was performed on the newborn, mother and other twin blood samples, as follows: (i) malaria rapid diagnostic test (RDT); (ii) Giemsa-stained thick and thin blood smears for Plasmodium spp. identification and parasitaemia titration; (iii) molecular screening and typing of Plasmodium spp. by multiplex qualitative PCR assay based on 18S rRNA gene. Genotyping of Plasmodium falciparum isolates from mother and child was performed by neutral microsatellite and highly polymorphic marker amplification.

Conclusions

The maternal RDT sample was negative, while the infant RDT was positive; in both cases microscopy of blood smears and PCR showed infection with P. falciparum. Two of the genotypic molecular markers displayed different allelic variants between the two samples. This difference could imply infection multiplicity of the mother during the pregnancy, possibly harbouring more than one isolate, only one of them being transmitted to the newborn while the other persisting in the mother’s blood. Because of the increasing number of pregnant women coming from endemic areas for malaria, an accurate anamnesis of infant’s mother, and the inclusion of Plasmodium spp. research into TORCH screenings for mother-infant pair at birth, aiming at reducing morbidity and mortality associated to the disease might be suitable.

Keywords

  • Congenital malaria
  • HIV
  • Bicorial, biamniotic pregnancy
  • Malaria laboratory panel
  • Plasmodium falciparum genotyping

Background

Congenital malaria is usually defined as the detection of asexual forms of Plasmodium spp. in a blood sample of a neonate during the first week of life or later if there is no possibility of postpartum infection by a mosquito bite (out of malaria endemic area) [1]. Congenital malaria can be acquired by transmission of parasites from the mother to child during pregnancy or perinatally during labour [2]. Congenital malaria in endemic countries is considered a rare condition due to the protective factors as the protection supplied by the placenta, the passive transfer of maternal antibodies [3] and the protective effect of fetal haemoglobin [4, 5]. The incidence of congenital malaria is highly variable. The literature reported an incidence between 7 and 33% in endemic area [6, 7] with an apparent increasing rate during the last years as result of rising drug resistance, increasing virulence of the parasite, human immunodeficiency virus (HIV) infection [7, 8]. The high variability seems related to several factors such as the different diagnostic methods and sampling (cord blood vs peripheral blood) used to detect Plasmodium spp., and the area in which the epidemiologic analyses are performed [6, 9]. In non-endemic countries, cases of congenital malaria are rare: in Europe only one case of congenital Plasmodium falciparum malaria was reported in 2014 [10]; in the USA only 81 cases of congenital malaria were identified between the years 1966 and 2005 [11]. Hereby, the case of a congenital malaria in an HIV-exposed child is reported.

Case presentation

A 2-month-old male child was admitted to the Academic Department of Pediatrics of the Bambino Gesù Children’s Hospital (BGCH) due to anaemia and exposure to HIV. He was born prematurely in Italy by cesarean section at 34 weeks’ gestation after a bicorial, biamniotic pregnancy with birth weight of 2.080 kg. He was the first of non-identical twins. The mother was a 30-year-old migrant woman from Nigeria, who arrived in Italy at 27 weeks gestation. At presentation, she tested seropositive for HIV and cytomegalovirus (CMV) and started antiretroviral therapy. Her absolute lymphocyte count was 1410/µl; CD4 count and the HIV viral load were not reported in the documentation received from the Hospital where the mother was admitted in emergency when she arrived in Italy.

The twins were tested for HIV at birth with PCR for HIV-RNA searching. The female twin was positive for HIV and CMV infection, while the male twin was HIV negative at birth and treated with zidovudin as post-exposure prophylaxis for 6 weeks. TORCH screening (toxoplasmosis, rubella, cytomegalovirus, herpes simplex), abdominal and cerebral ultrasounds were performed to exclude other congenital infections on both twins. A week before admission at our Department the male twin was admitted to another hospital due to anaemia (Hb 5.1 g/dl), hence receiving a blood transfusion. On initial evaluation at BGCH, he was in good general condition, weighed 3.910 kg, with temperature of 36.5 °C, heart rate of 135 beats per minute, respiratory rate of 35 for minute. His abdomen was soft, the liver was palpable 4 cm below the right costal margin. The findings of the rest of the examination were unremarkable.

Laboratory tests at the admission, after a week from the first blood transfusion, revealed a leukocyte count of 12.000/mm3; a haemoglobin (Hb) level of 9.1 g/dl; a platelet count of 198.000/mm3 and a reticulocyte count of 169.000/mm3. His bilirubin level was 1.31 g/dl with direct bilirubin of 0.64 mg/dl; lactate dehydrogenase level of 945 UI/L and normal renal and liver function values.

A myelosuppression effect due to the zidovudin was initially hypothesized, then the haemoglobin concentration was monitored and a supportive therapy with folic acid and iron per os was started.

During hospitalization, a progressive decrease of Hb levels to 6.8 g/dl was observed, therefore, requiring additional blood transfusions. Causes of haemolytic anaemia and blood loss were excluded, due to persistently high reticulocyte count; also, direct and indirect Coombs and faecal occult blood tests were performed, resulting all of which were negative. Haemoglobin electrophoresis was also performed, although in the presence of blood transfusions, to exclude hereditary haemoglobinopathies. A subsequent physical examination was then performed, revealing an increase of spleen enlargement, also confirmed by ultrasound examination. A diagnostic of malaria was then considered.

Because of the infants’ age and the origin of the mother who came from an endemic area for malaria, the malaria panel provided in BGCH was performed on twins and mother’s blood. The panel included the following routine algorithm: (i) Rapid diagnostic test (RDT); (ii) microscopy of Giemsa-stained thick and thin blood smears for Plasmodium spp. identification (ID) and parasitaemia index assigned by two independent microscopists; (iii) molecular screening and typing of Plasmodium spp. by an end-point multiplex qualitative polymerase chain reaction (PCR) assay.

The RDT, based on either Plasmodium spp. lactate dehydrogenase (pLDH) and P. falciparum histidine-rich protein 2 (HRP2) antigens, was performed by using SD Bioline Malaria Antigen P.f/Pan (Standard Diagnostic), whose performance is periodically monitored by the World Health Organization Malaria Control Programmes [12].

Briefly, about PCR assay, DNA was extracted from 200 μl of EDTA blood with the QIAamp DNA Mini Kit (QIAGEN) and 5 μl of each DNA sample were probed with the 18S rRNA gene target of the multiplex PCR STAT-NAT Malaria Screening and Typing (Sentinel-Diagnostics). PCR products were visualized using 2.2% agarose (Lonza FlashGel®System) and a UV trans-illuminator BioRad.

The RDT for Plasmodium spp. was negative for mother and female infant specimens, while male infant resulted positive (Fig. 1). PCR analysis confirmed a positive result for mother and male twin, revealing a P. falciparum infection, while samples from the other twin were consistently negative with both techniques (Figs. 2, 3). Thick and thin blood films stained by Giemsa revealed trophozoite forms of P. falciparum with parasitaemia index of 1% for the male infant and < 1% for the mother. The RBCs of the mother infected with malarial parasites were of normal size and poly-parasitized by trophozoites (Fig. 4).
Fig. 1
Fig. 1

Pattern of RDT for the mother (a), the male twin (b), the female twin (c)

Fig. 2
Fig. 2

Plasmodium spp. screening by 18S rRNA targeting PCR. M DNA marker, (1/2) Mother’s sample replicates; (3/4) male infant’s sample replicates; (5/6) female infant’s sample duplicates; (7/8) male infant’s sample duplicates

Fig. 3
Fig. 3

Plasmodium falciparum typing by 18S rRNA targeting PCR. M DNA marker, (1) Mother’s sample; (2) male infant’s sample

Fig. 4
Fig. 4

Infant and maternal blood smears. AC Mother’s thin blood smear revealing P. falciparum immature trophozoites (ring forms) within erythrocytes. D, E Infant’s thin blood smear, obtained on the day of delivery, documenting the presence of P. falciparum trophozoites within erythrocytes

Genotyping of Plasmodium spp. isolates was carried out to identify infectious clones in both mother and infant. The genotyping was performed by amplification of a neutral microsatellite marker (MS-TA109) [13] and four highly polymorphic markers: P. falciparum merozoite surface protein 1 (Pfmsp1) and its allelic subfamilies (K1, RO33, MAD20) [14], P. falciparum merozoite surface protein 2 (Pfmsp2) and its allelic subfamilies (3D7, FC27) [14], P. falciparum histidine-rich protein 2 (Pfhrp2) and t P. falciparum histidine-rich protein 3 (Pfhrp3) [15]. For allele detections, PCR was done in a 25 μl PCR mixture containing 10 μl of extracted DNA, 1× of MgCl2 free buffer Fast Start Roche, 2 mM of MgCl2, 200 μM of dNTPs, 10 μM of each primer and 0.25 U of FastStart Taq polymerase Roche. The cycling conditions for Pfmsp1 were as follows: denaturation at 95 °C for 5 min, followed by 45 cycles at 94 °C for 30 min, annealing at 47 °C for 45 s and extension at 72 °C for 1.5 min and a final extension at 72 °C for 5 min. The cycling conditions for Pfmsp1/Pfmsp2 families were: 95 °C for 5 min followed by 45 cycles at 94 °C for 1 min, 55 °C for 45 s, 72 °C for 1.5 min, and a final extension at 72 °C for 5 min. The Pfhrp3 gene, FC27, K1 and TA109 microsatellites were amplified as described in Menegon et al. and Anderson et al. [13, 16]. The amplification products were analysed using a high-resolution capillary electrophoresis (QIAxcel Advanced system, Qiagen).

Genotypic characterization of P. falciparum isolates showed the presence of a single isolate in each of the analysed blood samples. All five P. falciparum polymorphic markers were genotyped for isolate present in the newborn’s infection, whereas only four markers (Ta109, Pfmsp1, Pfmsp2 and Pfhrp3) were successfully amplified for the maternal isolate. Both isolates belonged to the K1 and the FC27 allelic subfamilies. The comparison of allelic profiles, based on length polymorphism of analysed markers, showed dissimilar size alleles for two molecular markers, Pfmsp2 and Pfhrp3, indicating that two different parasite isolates were present in the mother and child at the time of blood collection, 2 month after delivery. Moreover, the amplification failure of Pfhrp2 gene in the maternal sample was presumable due to the hrp2—deletion in the isolate infecting the mother (Fig. 5).
Fig. 5
Fig. 5

Electronic image of the gel displaying PCR product sizes of the six molecular markers amplified from mother and newborn DNA samples. The markers Pfmsp2, FC27 (subfamily of Pfmsp2) and Pfhrp3 showed discordant genotypes between the two analyzed samples

Because of the P. falciparum ID in the male infant, oral administration of atovaquone/proguanil (125 mg/50 mg daily for 3 days) was immediately started. The parasitaemia index on infant’s blood performed after treatment confirmed the clearance of the parasites; the following blood exams revealed a normalization of Hb level.

Discussion and conclusions

This is the third case of congenital malaria ensued in a HIV-infected mother in a non-endemic country [11, 17]. A review of congenital malaria cases in non-endemic country, by referring to a period spanning the last 40 years was included. The database mined for data searching was PubMed and the keywords used were “congenital malaria cases” and “non-endemic countries”. The selected language was English. Congenital malaria is a rare disease in both non-endemic [10, 18] and endemic areas, the latter characterized by an incidence corresponding to 0.3–37% [19]. Among the 37 cases of congenital malaria in non-endemic country reported in the last 40 years, 21 (58%) were caused by Plasmodium vivax, including 1 in combination with Plasmodium malariae and 1 with P. falciparum; 8 by P. falciparum (22%); three cases caused by P. malariae and 2 by Plasmodium ovale (Table 1). Congenital malaria results from transplacental passage of parasites, which infect the infant in utero, or during delivery. Different mechanisms have been postulated: maternal transfusion into the fetal circulation, direct penetration of parasite through the chorionic villi or through premature separation of placenta [1]. Rarely, maternal history of malaria may not be reported and, therefore, it cannot be considered as a criterion for the diagnosis of congenital malaria [17]. Origin from endemic countries for malaria, fever during pregnancy, placental malaria and anaemia in the mother, are the main risk factors [1, 8].
Table 1

Congenital malaria cases reported in the last 40 years in non-endemic area [16]

Author/PMID

Endemic area

Interval time

Antenatal symptoms and treatment (if known)

Age at diagnosis

Symptoms at diagnosis

Plasmodium species and parasitemia

Haemoglobin level g/dl

Platelets count/µl

HIV status

Treatment

Country of diagnosis

Vernes et al. 1978

PMID: 353713

Cambodia

2 months

F 1 day after delivery

20 days

F

P. vivax

Normal

Normal

Unknown

Chloroquine

France

Excler et al. 1980

PMID: 6987619

Cambodia

1 year

F

1 day

F, liver and spleen enlargement

P. vivax

8

172,000

Unknown

Chloroquine

France

Lajarrige

PMID: 18307546

Asia

Unknown

Delivery at home

12 days

F, paleness, LSE

P. vivax

3.8

159,000

Unknown

Chloroquine

France

Bour´ee et al. 1983

PMID:6340844

Cameroon

15 days

F

Birth

Lack of reactivity

P. falciparum

Unknown

85,000

Unknown

Unknown

France

Ch´eron et al. 1986

PMID:3813804

Guinea

7 months

Malaria during pregnancy

19 days

F

P. ovale

10

134,000

Unknown

Chloroquine

France

Peigne et al. 1987

PMID:3318635

Pakistan

4 days

Malaria 4 days after delivery

50 days

F, LSE, neurological

P. vivax

4.3

12,000

Unknown

Chloroquine

France

Poirrier

PMID:18307546

Madagascar

17 months

F/chloroquine

19 days

F

P. vivax 1.3%

6.1

188,000

Unknown

Chloroquine

France

Ligny et al. 1989

PMID:2696411

Mali

18 days

Malaria during pregnancy

28 days

Paleness, LSE

P. falciparum 1.5%

5.2

Unknown

Unknown

Chloroquine

France

Hennequin et al. 1991

PMID:1819395

Cameroon

15 days

F

Birth

LSE, lethargy

P. falciparum 0.1%

Unknown

Unknown

Unknown

Chloroquine

France

Romand et al. 1994

PMID:8078837

Togo

14 months

F

60 days

F, paleness, LSE

P. falciparum

6.3

Unknown

Unknown

Halofantrine

France

Niyongabo et al. 1989

PMID:2654272

Laos

2 years

Quinine

19 days

F, haemolysis, irritability

P. vivax and P. malariae

10.8

60,000

Unknown

Quinine and chloroquine

France

Hindi and Azimi. 1980

PMID:7005857

Nigeria

1 year

Malaria during pregnancy

35 days

F, anaemia, LSE

P. falciparum

8.7

257,000

ng

Chloroquine

California

Park et al. 1984

PMID:12891034

Africa

0

Malaria during pregnancy

39 days

F, poor feeding, paleness, LSE

P. vivax 1%

12.6

45,000

ng

Chloroquine

Korea

Gouyon et al. 1986

PMID:3530172

Guyana

6 months

Malaria during pregnancy/4-aminoquinolein

21 days

F, poor feeding, paleness, LSE

P. vivax 1%

12.6

45,000

ng

Chloroquine

France

Lynk and Gold 1989

PMID:2594448

India (two cases)

6 months, 13 months

F during third trimester

28 days, 35 days

Irregular F, anorexia and lethargy, LSE, anaemia and thrombocytopeaenia

P. vivax

4.1 and 5.9

47,000

Unknown

Chloroquine

Canada

Joffe and Jadavji 1990

PMID:2196518

India (two cases)

9 months

Malaria (P. vivax) during pregnancy/chloroquine

21 days

F, diarrhoea, poor feeding, LSE, anaemia neutropenia and thrombocytopaenia

P. vivax

1

57,000

Unknown

Chloroquine

Canada

Subramanian et al. 1992

PMID:1520785

Salvador

4 months

F/antibiotics

15 days

F, coryza, anaemia

P. vivax

Unknown

52,000

Unknown

Chloroquine

Texas

Hulbert 1992

PMID:1576289

Guatemala

1 year

Asthenia

30 days

F, LSE, diarrhoea, anaemia

P. vivax

6.6

70,000

Unknown

Chloroquine

California

Alves 1995

PMID:14689015

Brazil

40 days

Unknown

14 days

Unknown

P. vivax

Unknown

Unknown

Unknown

Unknown

São Paulo State

Lee et al. 1996

PMID:9046213

Pakistan

Unknown

F/Ibuprofen

60 days

F, anaemia, haemolysis, cough, paleness, LSE

P. vivax

5.3

69,000

ng

Chloroquine

Singapore

Marques et al. 1996

PMID:14688962

Brazil (two cases)

Unknown

Malaria during pregnancy

Unknown

Anaemia, LSE

P. vivax, P. falciparum

Unknown

Unknown

Unknown

unknown

São Paulo state

Kuyucu et al.1999

PMID:10770683

Turkey

Unknown

F and chills/Chloroquine

19 days

F, poor feeding, haemolysis, anaemia, LSE

P. vivax

8.5

50,000

ng

Chloroquine

Turkey

Niederer and Loeffler 1999

PMID:9951993

India

1 year

Unknown

23 days

F, cough, irritability, poor feeding, anaemia, leucopaenia, thrombocytopaenia

P. vivax

10.7

27,000

Unknown

Chloroquine

California

Romero Urbano et al. 2000

PMID:11003930

Guinea

1 month

Unknown

21 days

F, anaemia, thrombocytopenia

P. falciparum

Unknown

Unknown

Unknown

Mefloquine

Spain

Zenz et al. 2000

PMID:10890139

Ghana

18 months

Unknown

56 days

F, LSE, anaemia

P. falciparum and P. malariae

8.3

Unknown

Unknown

Chloroquine

Germany

D’avanzo

MMWR, March 1, 2002/51(08); 16-5

Congo

5 years

Malaria 5 years before pregnancy/chloroquine

21 days

F, dark urine, respiratory troubles, anaemia

P. malariae

6.6

109,000

ng

Chloroquine

North Carolina, USA

Olowu et al. 2002

PMID:12221966

Nigeria

 

Unknown

8 h

unknown

unknown

Unknown

Unknown

Unknown

Chloroquine

Osun State, Nigeria

Doraiswamy

CDC-MMRW

April 22, 2005/54(15);383–384

Guatemala

5 months

F, coryza

49 days

Moderate F, anaemia

P. vivax

6.2

Unknown

Unknown

Chloroquine

New York, USA

Siriez et al. 2005

PMID:16465819

Congo

2 years

Unknown

42 days

F, haemolysis, anaemia, thrombocytopaenia, poor feeding, LSE

P. malariae 3%

5.8

110,000

HIV-1

Chloroquine

France

Del Castillo et al. 2017

PMID:28077745

Nigeria

3 months

Pueperal F, thrombocytopenia during delivery

14 days

F, cough

P. falciparum 5.4%

Unknown

Unknown

Unknown

Quinidine and Clindamycin

Washington (Columbia)

Del Punta et al. 2010

PMID:20193072

Pakistan

1 year

F, anaemia, thrombocytopenia during delivery

22 days

F, paleness, whining cry, liver and spleen enlargement,

P. vivax 2%

12.3

14,000

Unknown

Chloroquine

Italy

Voittier et al. 2008

PMID:18307546

Guyana

6 months

malaria P. vivax/4-aminoquinoline

21 days

F, paleness, liver and spleen enlargement

P. vivax 1%

12.6

45,000

Unknown

Chloroquine

France

Voittier et al.2008

PMID:18307546

Angola

3 years

HIV

19 days

F, poor feeding

P. ovale 2%

12

38,000

ng

Chloroquine

France

Hagmann et al. 2007

PMID:17505278

Honduras

9 months

Malaria during pregnancy

26 days

F, cough, runny nose

P. vivax 4–5%

11.4

313,000

Unknown

Chloroquine

New York, USA

De Pontual et al. 2006

PMID:17030531

Congo

2 years

HIV

42 days

F, liver and spleen enlargement

P. malariae 1.8%

6.4

122,000

ng

Chloroquine

France

Hewson et al. 2003

PMID:14629507

India

4 months

F, abdominal pain, rigors

19 days

Apnoea, bradycardia

P. vivax

12.2

95,000

Unknown

Chloroquine

South Australia

F fever, LSE liver spleen enlargement, ng negative

HIV infection increases susceptibility to malaria during pregnancy [7] and it is associated with higher parasite density, higher risk of maternal and fetal anaemia, intra-uterine growth retardation (IUGR) and pre-term delivery [20], and low birth weight (LBW) in the neonates [21]. Recently a higher prevalence of congenital malaria in infants of mothers co-infected with HIV and malaria have been reported [8]. HIV infection compromised maternal immunity though an impairment of antibody responses with a higher risk of P. falciparum transmission [22]. However, the mechanism by which HIV increases susceptibility to malaria is not known. After birth, the mother may have a normal physical examination and negative blood malaria parasite [17]. In the present case, the mother never suffered from fever or symptoms suggestive for malaria during pregnancy. In women from endemic countries for malaria and with previous episodes of malaria it is common to be asymptomatic because of the immunity developed during the time [23].

In most cases of congenital malaria, the diagnosis is made at 10–28 days of age; 20 of the 37 published cases (56%) were diagnosed before 21 days (Table 1). The symptoms are rarely detected at birth, possibly because of the presence of IgG transferred from the mother during the pregnancy, and the protective effect of HbF; indeed, the passive immunity may prevent delay the onset of congenital malaria up to 6 weeks [24].

Clinical features of congenital malaria include fever, anaemia, thrombocytopaenia, liver and spleen enlargement. Jaundice, regurgitation, loose stools and poor feeding, occasionally apnea and cyanosis have also been reported [1]. Such clinical features may be confused with bacterial or viral infection, leading to a delay in diagnosis [25]. The patient presented anaemia with high level of reticulocyte. He needed a blood transfusion every week, a progressive spleen enlargement was noted. Initially toxicity by antiretroviral therapy was hypothesized because of the good clinical condition and the absence of symptoms and signs suggestive for infection. No fever was detectable during the entire hospitalization. Five other cases of congenital malaria without fever have been described (Table 1). In this case, there was not record of the exact onset of anaemia because blood tests were not performed during the period 7–30 days after birth. Likely, the anaemia occurred days and even weeks before admission to hospital.

The mother of the infant travelled during pregnancy in region where a high percentage of P. falciparum chloroquine resistance is reported, finally arriving to a non-endemic country [26, 27]. Because of the stable clinical condition and for the suspect of chloroquine resistance, the authors decided to treat the infant, with atovaquone/proguanil according to CDC guidelines [28]. Because the parasitaemia index was 1% and no criteria of severe malaria were present, oral administration was considered as appropriate treatment. Plasmodium spp. on female twin’s blood was absent, as reported for other cases in the literature [2936]. Peripheral maternal and peripheral newborn’s parasite populations was analysed 2 month after delivery to compare allelic profile of persistent P. falciparum isolates. Two different parasite isolates in the mother and child at the time of blood collection were found. Likely during the gestation the mother was parasitized by different P. falciparum strains, as supported by literature data [37]. It is conceivable for the mother to have harboured more than one isolate during pregnancy, only one of them being transmitted to the newborn and the different one having persisted in the mother’s blood after delivery [38].

Malaria RDTs are useful tools to confirm presence of malaria. Under optimal conditions, the sensitivity of the RDTs is considered similar to that of direct microscopy [39]. However, their execution may be questionable since on a number of occasions false negative results have been encountered which would negatively affect proper early therapeutic intervention. The three main groups of antigens detected by RDTs are HRP2, produced by trophozoites and young gametocytes of P. falciparum only; pLDH enzyme (P. falciparum specific, P. vivax specific or pan specific), and aldolase pan-specific enzyme [40].

In the presented case, RDTs of peripheral blood failed to detect a maternal infection, while PCR and microscopy were highly effective. PfHRP2 is a histidine and alanine-rich protein, characterized by a highly polymorphic repeat domain and represents the most common malaria antigen targeted by RDTs for the specific diagnosis of P. falciparum [41]. Frequently, another protein of P. falciparum, the PfHRP3 antigen [42], is recognized by PfHRP2-based RDTs [40, 43]. The above studies further revealed that polymorphisms of the Pfhrp2/3 genes can affect the performance of HRP2-based RDTs in term of sensitivity up to total test failure (false-negative), recommending molecular investigation. False negatives can be also due to impairment in host and parasite density, or antigen concentration.

Finally, P. falciparum parasites not expressing PfhHRP2 and/or PfHRP3 antigens have been reported [44]. These results are consistent with those reported in the literature [4549], and suggest that diagnostic guidelines for malaria be revisited.

The negative RDT in the mother can be justified by a low parasitaemia index and by the possible deletion of the Pfhrp2 gene in this parasite. As in the present case, the discordance in vertical transmission of malaria in bicorial and biamniotic pregnancy is reported in the literature [29], as well for CMV, HIV and toxoplasmosis [32, 33, 35]. Therefore, the same pathogenesis was supposed for the present case.

Conclusion

A prompt diagnosis of congenital malaria is crucial. The increasing number of pregnant women travelling from endemic areas for malaria to non-endemic countries, calls for routine investigation of Plasmodium spp. in women and neonates at risk: (i) women and pregnant women from endemic area for malaria, (ii) all neonates and infants with fever, anaemia, thrombocytopaenia and hepatosplenomegaly with mother who have travelled or lived in non-endemic area for malaria (Fig. 6).
Fig. 6
Fig. 6

Hypothesis of diagnostic algorithm for congenital malaria. Asterisk If PCR for Plasmodium spp is available in the Hospital

In such cases, accurate anamnesis of neonate’s mother and inclusion of Plasmodium spp. search into the TORCH screening for mother and infant at birth should be performed, to avoid delay in the diagnosis and to reduce morbidity and mortality associated to the disease. The differential diagnosis between neonatal malaria vs neonatal sepsis is not easily to be resolved by the use of clinical features alone. However, also the laboratory diagnosis of low parasitaemia, such as that observed in mother-infant pair infections, require high level of expertise in malaria diagnostic panels. Use of malaria RDT assays that can detect antigens other than PfHRP2 and pLDH should could be strongly encouraged in field setting but also in hospitals, in order to enhance malaria diagnosis. Advanced malaria diagnostic panels, when possible, can be decisive to monitor both congenital and other malaria infections during perinatal and paediatric ages.

Notes

Abbreviations

HIV: 

human immunodeficiency virus

TORCH: 

toxoplasmosis, rubella, cytomegalovirus, herpes simplex

RDT: 

rapid diagnostic test

LDH: 

lactate dehydrogenase

hrp2: 

histidine-rich protein 2

MS-TA109: 

microsatellite-(TA)n

Pfmsp1

Plasmodium falciparum merozoite surface protein 1

Pfmsp2

Plasmodium falciparum merozoite surface protein 2

Pfhrp3

Plasmodium falciparum histidine-rich protein 3

LBW: 

low birth weight

IUGR: 

intra-uterine growth retardation

WHO: 

World Health Organization

Declarations

Authors’ contributions

All authors have made substantial contributions to the investigations presented in this manuscript. PP and LP made the diagnosis, supervised all data collection and participated in drafting the manuscript; LR drafted the manuscript; SB, PP and HT clinically followed-up the mother and the child, SP, MM, GF, LP and CS carried out the molecular and genotyping studies. SP, SB, MM, CS, HT and AOM, revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We want to thank the patient who participated in this study, and the staff of Fondazione Siniscalco Ceci Emmaus Onlus. We thank Valeria Marzano for advice in figure preparation.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Upon request emoscopic and DNA materials are available.

Consent for publication

A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate

Written informed consent was obtained from the mother for her participation and that of her baby for the publication of this case report.

Funding

This study was supported by internal grant from “Bambino Gesù Children’s Hospital” (RC 2018) to Paolo Palma and by CCM 2015 AMR to Lorenza Putignani (http://www.ccm-network.it/pagina.jsp?id=node/2075&idP=740&idF=1870).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Immunology and Infectious Diseases, Research Unit in Congenital and Perinatal Infections, University-Hospital, Pediatric Department (DPUO), Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00165 Rome, Italy
(2)
Unit of Parasitology, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00165 Rome, Italy
(3)
Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, 00161 Rome, Italy
(4)
Department of Laboratories, Bambino Gesù Children’s Hospital, Piazza Sant’Onofrio 4, 00165 Rome, Italy
(5)
Unit of Human Microbiome, Bambino Gesù Children’s Hospital, Viale San Paolo 15, 00146 Rome, Italy

References

  1. Menendez C, Mayor A. Congenital malaria: the least known consequence of malaria in pregnancy. Semin Fetal Neonatal Med. 2007;12:207–13.PubMedView ArticleGoogle Scholar
  2. D’Alessandro U, Ubben D, Hamed K, Ceesay SJ, Okebe J, Taal M, et al. Malaria in infants aged less than six months-is it an area of unmet medical need? Malar J. 2012;11:400.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature. 1961;192:733–7.PubMedView ArticleGoogle Scholar
  4. Billig EM, McQueen PG, McKenzie FE. Foetal haemoglobin and the dynamics of paediatric malaria. Malar J. 2012;11:396.PubMedPubMed CentralView ArticleGoogle Scholar
  5. Shear HL, Grinberg L, Gilman J, Fabry ME, Stamatoyannopoulos G, Goldberg DE, et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood. 1998;92:2520–6.PubMedGoogle Scholar
  6. Falade C, Mokuolu O, Okafor H, Orogade A, Falade A, Adedoyin O, et al. Epidemiology of congenital malaria in Nigeria: a multi-centre study. Trop Med Int Health. 2007;12:1279–87.PubMedView ArticleGoogle Scholar
  7. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.PubMedView ArticleGoogle Scholar
  8. Eki-Udoko FE, Sadoh AE, Ibadin MO, Omoigberale AI. Prevalence of congenital malaria in newborns of mothers co-infected with HIV and malaria in Benin city. Infect Dis (Lond). 2017;49:609–16.View ArticleGoogle Scholar
  9. Carlier Y, Truyens C, Deloron P, Peyron F. Congenital parasitic infections: a review. Acta Trop. 2012;121:55–70.PubMedView ArticleGoogle Scholar
  10. European Centre for Disease Prevention and Control. Annual epidemiological report 2016. 2014 data. https://ecdc.europa.eu/en/publications-data/malaria-annual-epidemiological-report-2016-2014-data. Accessed 19 Nov 2015.
  11. Del Castillo M, Szymanski AM, Slovin A, Wong EC, DeBiasi RL. Congenital Plasmodium falciparum malaria in Washington, DC. Am J Trop Med Hyg. 2017;96:167–9.PubMedPubMed CentralView ArticleGoogle Scholar
  12. Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 6. 2014–2015. http://www.who.int/malaria/publications/atoz/9789241510035/en/. Accessed Dec 2015.
  13. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology. 1999;119:113–25.PubMedView ArticleGoogle Scholar
  14. Soulama I, Nébié I, Ouédraogo A, Gansane A, Diarra A, Tiono AB, et al. Plasmodium falciparum genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso. Malar J. 2009;8:135.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, et al. Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based rapid diagnostic tests. J Infect Dis. 2005;192:870–7.PubMedView ArticleGoogle Scholar
  16. Menegon M, L’Episcopia M, Nurahmed AM, Talha AA, Nour BYM, Severini C. Identification of Plasmodium falciparum isolates lacking histidine-rich protein 2 and 3 in Eritrea. Infect Genet Evol. 2017;55:131–4.PubMedView ArticleGoogle Scholar
  17. Vottier G, Arsac M, Farnoux C, Mariani-Kurkdjian P, Baud O, Aujard Y. Congenital malaria in neonates: two case reports and review of the literature. Acta Paediatr. 2008;97:505–8.PubMedView ArticleGoogle Scholar
  18. Prior AR, Prata F, Mouzinho A, Marques JG. Congenital malaria in a European country. BMJ Case Rep. 2012. https://doi.org/10.1136/bcr-2012-007310.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Olupot-Olupot P, Eregu EIE, Naizuli K, Ikiror J, Acom L, Burgoine K. Neonatal and congenital malaria: a case series in malaria endemic eastern Uganda. Malar J. 2018;17:171.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Moya- Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. Malar J. 2014;13:271.PubMedPubMed CentralView ArticleGoogle Scholar
  21. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg. 2004;71(2 Suppl):41–54.PubMedView ArticleGoogle Scholar
  22. Naniche D, Serra-Casas E, Bardají A, Quintó L, Dobaño C, Sigauque B, et al. Reduction of antimalarial antibodies by HIV Infection is associated with increased risk of Plasmodium falciparum cord blood infection. J Infect Dis. 2012;205:568–77.PubMedView ArticleGoogle Scholar
  23. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis. 2007;7:105–17.PubMedView ArticleGoogle Scholar
  24. Mohan K, Omar BJ, Singh RD, Maithani MM, Chaurasia RN. Clinico-hematological features and management outcome in neonatal malaria: a nine years analysis from North India. Curr Pediatr Rev. 2016;12:286–91.PubMedView ArticleGoogle Scholar
  25. Del Punta V, Gulletta M, Matteelli A, Spinoni V, Regazzoli A, Castelli F. Congenital Plasmodium vivax malaria mimicking neonatal sepsis: a case report. Malar J. 2010;9:63.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Hagmann S, Khanna K, Niazi M, Purswani M, Robins EB. Congenital malaria, an important differential diagnosis to consider when evaluating febrile infants of immigrant mothers. Pediatr Emerg Care. 2007;23:326–9.PubMedView ArticleGoogle Scholar
  27. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis. 2001;184:770–6.PubMedView ArticleGoogle Scholar
  28. Centers for Disease control and Prevention CDC. Treatment of malaria (guidelines for clinicians). 2013. https://www.cdc.gov/malaria/resources/pdf/clinicalguidance. Accessed July 2013.
  29. Balatbat AB, Jordan GW, Halsted C. Congenital malaria in a nonidentical twin. West J Med. 1995;162:458–9.PubMedPubMed CentralGoogle Scholar
  30. Linden VV, Linden HV Jr, Leal MC, Rolim Filho EL, Linden AV, Aragão MFVV, et al. Discordant clinical outcomes of congenital Zika virus infection in twin pregnancies. Arq Neuropsiquiatr. 2017;75:381–6.PubMedView ArticleGoogle Scholar
  31. Lazzarotto T, Gabrielli L, Foschini MP, Lanari M, Guerra B, Eusebi V, et al. Congenital cytomegalovirus infection in twin pregnancies: viral load in the amniotic fluid and pregnancy outcome. Pediatrics. 2003;112:e153–7.PubMedView ArticleGoogle Scholar
  32. Thapa R, Banerjee P, Akhtar N, Jain TS. Discordance for congenital toxoplasmosis in twins. Indian J Pediatr. 2009;76:1069–70.PubMedView ArticleGoogle Scholar
  33. de Martino M, Tovo PA, Galli L, Caselli D, Gabiano C, Mazzoni PL, et al. HIV-I infection in perinatally exposed siblings and twins: the Italian register for HIV infection in children. Arch Dis Child. 1991;66:1235–8.PubMedPubMed CentralView ArticleGoogle Scholar
  34. Barlow KM, Mok JY. Dizygotic twins discordant for HIV and hepatitis C virus. Arch Dis Child. 1993;68:507.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Egaña-Ugrinovic G, Goncé A, García L, Marcos MA, López M, Nadal A, et al. Congenital cytomegalovirus infection among twin pairs. J Matern Fetal Neonatal Med. 2016;29:3439–44.PubMedGoogle Scholar
  36. Tomasik T, Zawilińska B, Pawlik D, Ferek J, Ferek J, Wójtowicz A, et al. Congenital cytomegaly in one twin: a case report. Med Wieku Rozwoj. 2012;16:252–60.PubMedGoogle Scholar
  37. Mwangoka GW, Kimera SI, Mboera LE. Congenital Plasmodium falciparum infection in neonates in Muheza District, Tanzania. Malar J. 2008;7:117.PubMedPubMed CentralView ArticleGoogle Scholar
  38. Castellanos MN, Bardaji A, Menegon M, Mayor A, Desai M, Severini C, et al. Plasmodium vivax congenital malaria in an area of very low endemicity in Guatemala: implications for clinical and epidemiological surveillance in a malaria elimination context. Malar J. 2012;11:411.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Ho MF, Baker J, Lee N, Luchavez J, Ariey F, Nhem S, et al. Circulating antibodies against Plasmodium falciparum histidine-rich proteins 2 interfere with antigen detection by rapid diagnostic tests. Malar J. 2014;13:480.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Baker J, Ho MF, Pelecanos A, Gatton M, Chen N, Abdullah S, et al. Global sequence variation in the histidine-rich proteins 2 and 3 of Plasmodium falciparum: implications for the performance of malaria rapid diagnostic tests. Malar J. 2010;9:129.PubMedPubMed CentralView ArticleGoogle Scholar
  41. Howard RJ, Uni S, Aikawa M, Aley SB, Leech JH, Lew AM, et al. Secretion of a malarial histidine-rich protein (Pf HRP II) from Plasmodium falciparum-infected erythrocytes. J Cell Biol. 1986;103:1269–77.PubMedView ArticleGoogle Scholar
  42. Wellems TE, Howard RJ. Homologous genes encode two distinct histidine-rich proteins in a cloned isolate of Plasmodium falciparum. Proc Natl Acad Sci USA. 1986;83:6065–9.PubMedView ArticleGoogle Scholar
  43. Lee N, Baker J, Bell D, McCarthy J, Cheng Q. Assessing the genetic diversity of the aldolase genes of Plasmodium falciparum and Plasmodium vivax and its potential effect on performance of aldolase-detecting rapid diagnostic tests. J Clin Microbiol. 2006;44:4547–9.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Cheng Q, Gatton ML, Barnwell J, Chiodini P, McCarthy J, Bell D, et al. Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. Malar J. 2014;13:283.PubMedPubMed CentralView ArticleGoogle Scholar
  45. Koita OA, Doumbo OK, Ouattara A, Tall LK, Konaré A, Diakité M, et al. False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. Am J Trop Med Hyg. 2012;86:194–8.PubMedPubMed CentralView ArticleGoogle Scholar
  46. Wurtz N, Briolant S, Lemarié D, Pommier de Santi V, Pascual A, Roodt T, et al. Delayed diagnosis of Plasmodium falciparum in a soldier in Uganda: false-positive rapid diagnostic test associated with reduced repeats in pfhrp2. Med Sante Trop. 2013;23:181–4.PubMedGoogle Scholar
  47. Amoah LE, Abankwa J, Oppong A. Plasmodium falciparum histidine rich protein-2 diversity and the implications for PfHRP 2: based malaria rapid diagnostic tests in Ghana. Malar J. 2016;15:101.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Parr JB, Belson C, Patel JC, Hoffman IF, Kamthunzi P, Martinson F, et al. Estimation of Plasmodium falciparum transmission intensity in Lilongwe, Malawi, by microscopy, rapid diagnostic testing, and nucleic acid detection. Am J Trop Med Hyg. 2016;95:373–7.PubMedPubMed CentralView ArticleGoogle Scholar
  49. Kozycki CT, Umulisa N, Rulisa S, Mwikarago EI, Musabyimana JP, Habimana JP, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact of Plasmodium falciparum isolates lacking hrp2 and declining malaria transmission. Malar J. 2017;16:123.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© The Author(s) 2018

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement